Arcturus Financial Statements From 2010 to 2026
| ARCT Stock | USD 6.61 0.24 3.77% |
Check Arcturus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arcturus Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Arcturus financial statements analysis is a perfect complement when working with Arcturus Therapeutics Valuation or Volatility modules.
Check out the analysis of Arcturus Therapeutics Correlation against competitors. Arcturus Therapeutics Holdings Company Current Valuation Analysis
Arcturus Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Arcturus Therapeutics Current Valuation | 23.21 M |
Most of Arcturus Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Arcturus Therapeutics Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Arcturus Therapeutics Holdings has a Current Valuation of 23.21 M. This is 99.84% lower than that of the Biotechnology sector and 99.5% lower than that of the Health Care industry. The current valuation for all United States stocks is 99.86% higher than that of the company.
Arcturus Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Arcturus Therapeutics's current stock value. Our valuation model uses many indicators to compare Arcturus Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Arcturus Therapeutics competition to find correlations between indicators driving Arcturus Therapeutics's intrinsic value. More Info.Arcturus Therapeutics Holdings is rated third in return on equity category among its peers. It is rated second in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Arcturus Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.About Arcturus Therapeutics Financial Statements
Arcturus Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Arcturus Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Arcturus Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Arcturus Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company was founded in 2013 and is headquartered in San Diego, California. Arcturus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 177 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Arcturus Stock Analysis
When running Arcturus Therapeutics' price analysis, check to measure Arcturus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcturus Therapeutics is operating at the current time. Most of Arcturus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arcturus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcturus Therapeutics' price. Additionally, you may evaluate how the addition of Arcturus Therapeutics to your portfolios can decrease your overall portfolio volatility.